Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment ... -

21-10-2013 News-Medical.netComments (0)

BiotechnologyCytos Biotechnology

Cytos Biotechnology Ltd (SIX:CYTN) ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003. This study investigates the effectiveness, safety and tolerability of ...


Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top